3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Stomach Neoplasms
12
Colorectal Neoplasms
10
Adenocarcinoma
6
Breast Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Sarcoma
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
Imatinib Mesylate
71
Sunitinib
31
regorafenib
17
nilotinib
15
ripretinib
13
avapritinib
7
Laparoscopy
5
Ipilimumab
5
Dasatinib
5
spartalizumab
4
CTLA-4 Antigen
4
Blood Specimen Collection
4
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
4
pexidartinib
3
pazopanib
3
binimetinib
3
Temozolomide
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Oxaliplatin
3
Observation
3
Nivolumab
3
Midazolam
3
Leucovorin
3
Gemcitabine
3
Biopsy
3
Bevacizumab
3
trametinib
2
tanespimycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
trastuzumab deruxtecan
×
Gastrointestinal
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled